UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 22 von 64
Datensatz exportieren als...
BibTeX
Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer
Radiology. Imaging cancer, 2023-03, Vol.5 (2), p.e220022-e220022
Ravi, Harshan
Arias-Lorza, Andres M
Costello, James R
Han, Hyo Sook
Jeong, Daniel K
Klinz, Stephan G
Sachdev, Jasgit C
Korn, Ronald L
Raghunand, Natarajan
2023
Details
Autor(en) / Beteiligte
Ravi, Harshan
Arias-Lorza, Andres M
Costello, James R
Han, Hyo Sook
Jeong, Daniel K
Klinz, Stephan G
Sachdev, Jasgit C
Korn, Ronald L
Raghunand, Natarajan
Titel
Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer
Ist Teil von
Radiology. Imaging cancer, 2023-03, Vol.5 (2), p.e220022-e220022
Ort / Verlag
United States: Radiological Society of North America
Erscheinungsjahr
2023
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
Purpose To investigate ferumoxytol (FMX)-enhanced MRI as a pretreatment predictor of response to liposomal irinotecan (nal-IRI) for thoracoabdominal and brain metastases in women with metastatic breast cancer (mBC). Materials and Methods In this phase 1 expansion trial (ClinicalTrials.gov identifier, NCT01770353; 27 participants), 49 thoracoabdominal (19 participants; mean age, 48 years ± 11 [SD]) and 19 brain (seven participants; mean age, 54 years ± 8) metastases were analyzed on MR images acquired before, 1-4 hours after, and 16-24 hours after FMX administration. In thoracoabdominal metastases, tumor transverse relaxation rate (R* ) was normalized to the mean R* in the spleen (rR* ), and the tumor histogram metric rR* , representing the average of rR* in voxels above the th percentile, was computed. In brain metastases, a novel compartmentation index was derived by applying the MRI signal equation to phantom-calibrated coregistered FMX-enhanced MRI brain scans acquired before, 1-4 hours after, and 16-24 hours after FMX administration. The fraction of voxels with an FMX compartmentation index greater than 1 was computed over the whole tumor (FCIGT1) and from voxels above the 90th percentile R* (FCIGT1 R* ). Results rR* computed from pretherapy MRI performed 16-24 hours after FMX administration, without reference to calibration phantoms, predicted response to nal-IRI in thoracoabdominal metastases (accuracy, 74%). rR* performance was robust to the inclusion of some peritumoral tissue within the tumor region of interest. FCIGT1 R* provided 79% accuracy on cross-validation in prediction of response in brain metastases. Conclusion This first in-human study focused on mBC suggests that FMX-enhanced MRI biologic markers can be useful for pretherapy prediction of response to nal-IRI in patients with mBC. MRI Contrast Agent, MRI, Breast, Head/Neck, Tumor Response, Experimental Investigations, Brain/Brain Stem Clinical trial registration no. NCT01770353 © RSNA, 2023 See also commentary by Daldrup-Link in this issue.
Sprache
Englisch
Identifikatoren
ISSN: 2638-616X
eISSN: 2638-616X
DOI: 10.1148/rycan.220022
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10077095
Format
–
Schlagworte
Brain Neoplasms - diagnostic imaging
,
Brain Neoplasms - drug therapy
,
Breast Neoplasms - diagnostic imaging
,
Breast Neoplasms - drug therapy
,
Female
,
Ferrosoferric Oxide
,
Humans
,
Irinotecan - therapeutic use
,
Magnetic Resonance Imaging - methods
,
Middle Aged
,
Original Research
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX